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Background: Dietary carbohydrates may affect metabolic and physiologic parameters. The present study evaluated
whether a combination of two dietary fibers, oligofructose (OFS) and pectin (P), altered satiety and glycemic
parameters. The primary objective of this study was to determine whether dietary supplementation for 3 weeks
with OFS + P would produce a greater reduction in energy intake of an ad libitum test meal compared to control.
Methods: This was a single center, randomized, double-blind, placebo-controlled, parallel group study in overweight
and obese, otherwise healthy, subjects (N = 96). There were two OFS + P treatment groups: high-dose (30 g/d),
low-dose (15 g/d), and a control group (maltodextrin 15 g/d). Energy intake, appetite measures based on Satiety
Labeled Intensity Magnitude (SLIM) scale, fasting and post-prandial glucose, and insulin levels and body weight were
measured at baseline and at the end of 3 weeks. Adverse events and gastrointestinal tolerability of the treatments were
also assessed.
Results: An analysis of covariance (ANCOVA) performed on the primary endpoint change from baseline in energy
intake, showed no statistically significant difference in energy intake among the three treatment groups (p = 0.5387).
The LS mean changes (SE) in energy intake from baseline to week 3 were −58.3 (42.4) kilocalories (kcal) for the high
dose group, −74.2 (43.6) kcal for the low dose group, and −9.0 (42.9) kcal for the control group. For the pairwise
comparisons of OFS + P doses and control, confidence intervals were constructed around the difference in LS mean
changes. All study products were generally well tolerated.
Conclusion: There was a directional benefit in ad libitum energy intake for both OFS + P doses compared to control,
with a greater reduction in kilocalories in the low dose comparison, but the reductions were not significant. Further
studies are warranted.
Clinical trial registration: GSK Clinical Study Register # W7781293
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Satiety can be broadly defined as the feeling of fullness
and/or the inhibition of hunger sensations after a meal.
Appetite regulation has numerous determinants, includ-
ing food composition, digestion, gastric emptying, and
nutrient absorption, which together influence postprandial
satiety responses. Various types of dietary carbohydrates
differ considerably in the effects they exert on metabolic* Correspondence: rebecca.j.hodge@gsk.com
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tinal transit time. The term ‘dietary fiber’ encompasses a
variety of compounds that reach the colon undigested,
including insoluble fibers such as wheat bran, soluble
fibers from oats and fruits, resistant starches and oli-
gosaccharides. The effect that a specific fiber has on
satiety depends on its physical properties when eaten,
how it is metabolized in the gut and its resultant
physiological effects in the gut and elsewhere. In most
cases, the physiologic benefits of a fiber can be fur-
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when it is added to fluid; it is also associated with water-
holding properties. Several types of viscous fibers increase
satiety by increasing stomach distension which can slow
gastric emptying [1]. Another possible mechanism by
which fibers increase satiety is through fermentation in
the gut by microflora [2] and the subsequent effects of
short-chain fatty acids (SCFA) produced. SCFA interact
with G-coupled protein receptors such as GPR41 and
GPR43 on enteroendocrine cells [3] and may be part of
the mechanism for the effect of fiber on appetite as they
increase production of satiety-related hormones from the
colon [4-6].
Pectin (P) and oligofructose (OFS) are hypothesized to
evoke satiety via SCFA production in the colon [7]. A
small number of placebo-controlled trials demonstrated
effects of OFS supplementation on satiety, satiety-related
hormones, glycemic parameters, and weight loss in
humans [8-12], although other clinical studies have dem-
onstrated mixed or minimal effect [13]. Some clinical
studies also suggest that pectin alters satiety, satiety-
related hormones, glycemic parameters, and gastric
emptying [14-19]. No clinical studies have explored the
efficacy of a combination of OFS and pectin on these
endpoints.
This study examined whether dietary supplementa-
tion with a combination of OFS and pectin (OFS + P)
produces greater changes in satiety and glycemic pa-
rameters than a control oligosaccharide, maltodextrin
(CON). Two dose levels (“high” and “low”) of OFS + P
were tested. Measures of gastrointestinal tolerability and
adverse events (AEs) were also evaluated.
Methods
Study subjects
Ninety-six healthy volunteers aged 18–60 years, with a
BMI of 25.0 to < 35.0 kg/m2, consuming a usual diet of
three main meals (5–7 days/week) at the time of enroll-
ment, and who showed willingness to consume the re-
quired food, were recruited to participate in this study.
The main exclusion criteria included pregnancy or breast-
feeding, use of hormonal contraception, and history
of gastrointestinal disease having an impact on food
absorption or digestion, anorexia nervosa or bulimia
nervosa, hypoglycemia, cardiovascular disease, elevated
plasma glucose, unstable thyroid function, abnormal/
irregular menstrual cycle, substance abuse, or being on
medication having an effect on appetite. Subjects were
also excluded if they were participating in any weight
altering program, had a weight gain or loss of > 5 kg
in the 3 months prior to enrollment, or had a history
of intestinal discomfort when consuming relatively small
(e.g., < 10 g) amounts of non-digestible carbohydrates and/
or fibers.The subjects were enrolled and study completed be-
tween October and December, 2011, at Biofortis-Provident
Clinical Research, Addison, IL. Ethical approval for the
study was obtained from Quorum Review Institutional
Review Board (Reference no: QR# 26302/1). All par-
ticipants gave written informed consent before enter-
ing the study. The study adhered to the principles of
Declaration of Helsinki, ICH Good Clinical Practice,
and other applicable regulations.
Study design
This was a single-center, randomized, double-blind, placebo-
controlled, parallel-group study in overweight and obese
subjects, consisting of three separate clinic visits. Subject
eligibility was determined at Visit 1 (screening visit). See
Figure 1 for a study schematic.
Subjects who qualified for participation returned for
Visit 2 (within 14 days of the screening visit). After re-
assessment of the inclusion/exclusion criteria, the eli-
gible subjects underwent baseline evaluations for energy
intake, subjective measures of appetite, as well as gly-
cemic parameters. At this visit, subjects arrived at the
site in the evening (no later than 17:00) prior to testing.
They were provided with a standardized dinner (portion
sizes based on calculated energy needs), to be consumed
ad libitum, no later than 18:30, after which they com-
pleted an Eating Inventory. The Eating Inventory consists
of 51 items and measures three dimensions of eating mo-
tivation: restraint, disinhibition, and hunger [20]. Subjects
were confined to the site until the end of the test meal the
next day, and were restricted from consuming any food
after 21:30, but they could have water ad libitum until
07:00 the following morning. At approximately 07:30
(±10 min), fasting body weight was collected and an in-
dwelling venous catheter was placed in the peripheral
vein. Around 08:00 (±10 min), subjects completed a sub-
jective appetite questionnaire, followed within 5 minutes
by collection of a fasting blood sample to assess baseline
concentrations of glucose and insulin. A second fasting
blood sample was collected 4 min (±1 min) later to meas-
ure insulin levels for the calculation of the Homeostasis
Model Assessment Insulin Resistance (HOMA-IR) score
using the mean of the two fasting insulin values. At T0
(where “T” equals time and “0” equals zero min), five mi-
nutes after the second fasting blood sample, subjects con-
sumed 8 oz (=240 ml) of room temperature water
(vehicle) flavored with a commercially available water fla-
voring product (MiO®) (vehicle), followed by the mixed
meal breakfast, consisting of a nutritionally balanced meal
bar and a mixed fruit cup. At each time point, 15, 30, 60,
90, 120, 180 and 240 minutes, subjects completed the ap-
petite questionnaire and a blood sample was collected.
Subjects then consumed 8 oz of room temperature fla-
vored water (vehicle) followed by the lunch test meal
Figure 1 Study schematic.
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tortellini and pasta sauce to permit calculation of energy
intake based on weight of food consumed.
At the end of Visit 2, subjects were randomized to one
of three treatments (high-dose OFS + P, low-dose OFS + P,
or maltodextrin control) to be consumed three times a
day at meals. The randomization code was generated by
the Biostatistics department of GSK Consumer Healthcare
using a random number generator, and subjects were
assigned to treatment by the investigative site in order of
enrollment. The high-dose OFS + P contained 5.0 g OFS
and 5.0 g pectin, and the low-dose OFS + P contained
2.5 g OFS and 2.5 g pectin. Maltodextrin (2.5 g + 2.5 g)
was the placebo control in this study. The study treat-
ments were provided as two individual sachets affixed to-
gether, and were added to approximately 8 oz of cold/
room-temperature water and blended in a reusable ‘shaker’
bottle with a wire ball that was provided to the subjects. A
total of 66 doses (2 sachets × 3 doses, 22 days of the
assigned treatments) were provided to the subjects. For
three weeks the subjects prepared the study treatment be-
fore each meal, consumed it within approximately 5 min,
and documented the treatment compliance on a daily
diary card that subjects returned on the last visit.
Three weeks later, at Visit 3, the eligibility criteria were
reconfirmed, and Visit 2 procedures were repeated using
the study treatments instead of vehicle. At this visit, the
daily diary card and unused products were returned by
the subjects. AE data were collected by subject diary or
by self-report during the scheduled clinic visits of the
study and gastrointestinal tolerability was evaluated at
Visit 3 on the basis of a standardized questionnaire.
The commercially available water flavoring product was
provided to subjects at the time study treatment wasdispensed. Subjects were required to use the flavoring
product (approximately ½ teaspoon) in the clinic (Visits 2
and 3) to help mask the active and control treatments and
they were encouraged to use it during the 3 weeks of dos-
ing to improve compliance with treatment.
Packaging and labeling of all study products was carried
out according to current good manufacturing practices
(cGMP) guidelines. The study products were packaged
and labeled by Catalent Pharma Solutions, Philadelphia,
PA., and prepared/managed by the GSK Clinical Supplies
department. The clinical supplies were stored in a se-
cure, temperature-controlled area with access limited
to the investigator and authorized site personnel. Storage




As no clinical efficacy studies examining the combin-
ation of OFS + P on satiety have been reported, no for-
mal sample size calculation was performed. The sample
size chosen was comparable to those used in published
placebo-controlled trials demonstrating effects of OFS
supplementation on satiety and weight loss in humans
[8-12]. A sufficient number of healthy subjects were
screened by the study site to ensure approximately 96
subjects were randomized in order to yield at least 72
fully evaluable subjects, with approximately 24 subjects
per treatment group.
Study populations
All randomized subjects who consumed the study treat-
ment were considered evaluable for the safety popula-
tion. The intention-to-treat (ITT) population included
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ment and had energy intake assessments at the test meal
at baseline and week 3. The per-protocol (PP) popula-
tion included all ITT subjects who completed the study
without any major protocol deviations. Subjects were
excluded from the PP population if they did not meet
inclusion/exclusion criteria or took prohibited medication
or product prior to or during the study treatment, or did
not comply with product usage (took fewer than 54 doses
of study product).Efficacy variables
Primary efficacy parameter The primary efficacy end-
point was the change from baseline in energy intake
(kcal), defined as the difference between the test meal
intake at 3 weeks and baseline, in the active groups com-
pared to the control. The change from baseline to week
3 in energy intake was determined from the weight of
the standardized test meals consumed by the subjects at
lunch-time. At the test meal, the food was weighed prior
to and following the meal to determine the total food
intake, first at the baseline visit and then at the week 3
visit. Total food intake, recorded in grams (g), was con-
verted to kilocalories (kcal) to derive the energy intake
(conversion factor of 2.019 kcal/g, based on a 2120 kcal
meal). The difference in energy intake between the base-
line and week 3 visits was then calculated for each
subject.Secondary efficacy parameters The secondary efficacy
parameters in this study included: subjective appetite
ratings, fasting and post-prandial glucose, and insulin
values expressed as area-under-the-concentration curve
0-4 h (AUC0–4 h), and body weight.
The subjective appetite ratings were evaluated on the
basis of Satiety Labeled Intensity Magnitude (SLIM)
scale questionnaire [21]. The SLIM scale was rated on a
100 mm scale, from “greatest imaginable fullness” to
“greatest imaginable hunger”. The SLIM scale rated the
degree of hunger/fullness a subject felt at the point in
time that the measurement was taken, namely at times
0, 15, 30, 60, 90 120, 180, and 240 minutes. The AUC
for the SLIM scale ratings was calculated using the lin-
ear trapezoidal method applied to the observed ratings
in order to obtain a cumulative measurement of the
treatment effect on appetite characteristics across time.
For glucose and insulin, AUC0–4 h was calculated for
the baseline (Visit 2) and week 3 (Visit 3) assessments.
Actual time, in hours, relative to the start of the flavored
water intake (baseline) or study product intake (week 3)
was used to calculate the AUCs. The AUC was calcu-
lated using the linear trapezoid method for the mixed-
breakfast meal challenge glucose and insulin values.Body weight was measured at baseline and at the
week 3 visit, and the change from baseline to week 3
was calculated.Statistical methods for primary and secondary parameters
Descriptive statistics were computed for the primary and
secondary outcome variables. For the primary analysis,
linear modeling using analysis of covariance (ANCOVA)
explored the change from baseline in energy intake, with
treatment group as a factor, and baseline energy intake as
a covariate in the model. For the pair-wise comparisons in
least square (LS) means of the energy intake variable be-
tween the active treatments and the control, 95% confi-
dence intervals were calculated for these comparisons. If
the overall treatment effect was significant for the primary
efficacy variable, then a hierarchical testing procedure was
planned to adjust for multiplicity, and corresponding p-
values were calculated for the pair-wise comparisons.
The pre-treatment to post-treatment changes were sum-
marized for the secondary variables. In addition, HOMA-
IR [22] and the Matsuda Index [23] were calculated to
assess insulin resistance and insulin sensitivity, respect-
ively. ANCOVA was applied to the change from baseline
variables of SLIM scale (AUC), glucose (AUC), insulin
(AUC), and body weight, with treatment group as a factor,
and baseline value of the specific parameter included as a
covariate in the model. The pair-wise difference in the LS
means between each active product and control product
was calculated, and 95% confidence intervals (CI) were
constructed for these differences.
Results
Study subjects
A total of 160 subjects were screened, of which 96 sub-
jects were randomized to the study treatments. Subject
disposition is provided in Figure 2. The ITT population
included 88 (91.7%) subjects (30 in high-dose OFS + P
group, 29 in low-dose OFS + P group, and 29 in control
group) who had at least one post-randomization efficacy
measurement. The PP analysis included 81 (84.4%) sub-
jects (28 in high-dose OFS + P group, 27 in low-dose
OFS + P group, and 26 in control group) who did not
have any major protocol violations.
Overall, 51 (58.0%) females and 37 (42.0%) males con-
stituted the ITT population of the study. The demo-
graphic and baseline characteristics of these subjects are
provided in Table 1, and are comparable between the
groups. The mean (SD) age of the enrolled subjects was
41.6 (12.4) years. The high-dose OFS + P group had a
lower mean age and more females, compared to the
other two groups. The majority of the enrolled popula-
tion was Caucasian (70.5%). The mean (SD) body weight
of the subjects was 83.1 (12.8) kg (Table 1).
Figure 2 Subject disposition.
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by gender and overall for each treatment group. For the
three measurements, cognitive restraint of eating, disin-
hibition, and hunger, there were slightly higher scores for
females than males. The overall mean scores at baseline
(minimum, maximum scores) across all the treatmentTable 1 Demographic and baseline characteristics
Parameter High dose OFS + P (N = 30)









Body Weight (kg): Mean (SD) 81.4 (12.2)
BMI (kg/m2): Mean (SD) 29.3 (2.8)
Dietary fiber intake (g): Mean (SD) 17.1 (4.6)
Cognitive restraint of eating: Mean (SD) 8.9 (4.7)
Disinhibition: Mean (SD) 6.9 (3.8)
Hunger: Mean (SD) 6.6 (3.3)groups were 8.6 [1,21] for the cognitive restraint of eating,
7.1 (0, 16) for disinhibition, and 6.6 (0, 14) for hunger.
Subjects were considered compliant if they took at
least 54 of 66 doses of the study product. Compliance
(%) was achieved by 29 (96.7%) subjects in the high-dose
OFS + P group, 27 (93.1%) subjects in the low-doseLow dose OFS + P (N = 29) Control (N = 29) Overall (N = 88)
43.4 (11.8) 42.3 (12.8) 41.6 (12.4)
13 (44.8) 15 (51.7) 37 (42.0)
16 (55.2) 14 (48.3) 51 (58.0)
0 0 1 (1.1)
7 (24.1) 11 (37.9) 24 (27.3)
22 (75.9) 17 (58.6) 62 (70.5)
0 1 ( 3.4) 1 (1.1)
82.1 (12.7) 85.3 (13.8) 83.1 (12.8)
28.3 (2.6) 29.4 (2.7) 29.0 (2.7)
16.9 (4.4) 16.3 (3.1) 16.8 (4.0)
8.2 (4.8) 8.7 (4.4) 8.0 (4.6)
8.0 (4.3) 6.4 (3.5) 7.1 (3.9)
7.4 (3.8) 5.9 (3.4) 6.6 (3.5)
Table 2 Mean change from baseline to week 3: energy intake (Kcal) at the test meal
Parameter High dose OFS + P (N = 30) Low dose OFS + P (N = 29) Control (N = 29)
Energy intake at baseline: Mean (SD) 694.4 (301.4) 896.3 (449.7) 732.9 (372.4)
Energy intake at week 3: Mean (SD) 648.3 (337.2) 803.3 (455.6) 730.3 (381.8)
Mean change1 (SD) - 46.1 (236.7) - 93.0 (260.8) - 2.7 (208.7)
LS Mean change2 - 58.3 (42.4) - 74.2 (43.6) - 9.0 (42.9)
95% CI of LS mean change - 142.6, 26.1 - 160.8, 12.4 - 94.2, 76.3
Difference from control3 (SE) - 49.3 (60.1) - 65.2 (61.5)
95% CI of difference from control - 168.8, 70.2 - 187.5, 57.0
1Mean change was calculated as (Week 3 Mean–Baseline Mean).
2LS Mean Change adjusted for baseline energy intake effect, using analysis of covariance model.
3The difference from control is the difference in the LS Mean Changes of the active treatment minus the control. Overall treatment effect p-value = 0.5387.
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group, in the ITT population.
Efficacy results
Energy intake at the test meal
The adjusted mean changes of energy intake at the test
meal are summarized in Table 2. Overall, there was not
a statistically significant difference among the treatment
groups for energy intake (p = 0.5387). The LS mean
changes (SE) from baseline to week 3 were −58.3 (42.4)
kcal for the high-dose group, −74.2 (43.6) kcal for the low-
dose group, and −9.0 (42.9) kcal for the control
group. In the ITT population, the adjusted difference
(95% CI) between the high-dose group and control was -
49.3 (−168.8, 70.2) as compared to the difference between
the low-dose group and control of −65.2 (−187.5, 57.0).
Similarly, the difference among the treatment groups for
energy intake for the PP population was not signifi-
cant (p = 0.8265).
Subjective ratings of appetite (SLIM scale)
Appetite ratings increased in fullness from time 0
(fasting) to either 15 or 30 min post-meal, and then
began to decrease until the final measurement at 4 hours,
at both baseline and week 3. Mean scores of 50 indi-
cate the subjects are neither hungry nor full, while values
above 50 indicate degrees of fullness (highest degree
is 100 = greatest imaginable fullness), and below 50
indicate degrees of hunger (lowest degree is 0 = great-
est imaginable hunger). The mean scores crossed over
the midpoint from fullness to hunger between 2.0
and 3.0 hours for the high-dose OFS + P group, be-
tween 1.0 and 1.5 for the low-dose OFS + P group,
and between 1.5 and 2.0 for the control group, at both
baseline and week 3. The observed appetite ratings are
presented in Figure 3 for high-dose OFS + P, low-dose
OFS + P and control.
Table 3 presents the AUC0–4 hr results for the subject-
ive ratings of appetite. Overall, there was not a statisti-
cally significant difference among the treatment groups(p = 0.1279). The LS mean change from baseline to
week 3 was highest for the high-dose OFS + P group
at 13.8, followed by the low-dose OFS + P group at
6.9, and then the control group at −3.7. The differ-
ence in LS mean change (95% CI) was 17.5 (0.5, 34.5)
between the high-dose OFS + P group and the control
and 10.6 (−7.0, 28.3) between the low-dose OFS + P
group and the control.Concentrations of blood glucose and insulin
There was minimal change from baseline in fasting glu-
cose in all three treatment groups (Table 4). However,
after adjusting for baseline, the mean change from base-
line (SE) in glucose AUC showed an increase of 8.5 (5.04)
in the control group and reductions of 7.7 (4.95) and 3.0
(5.04) mg*hr/dL in the high and low dose OFS + P groups,
respectively. The difference in the LS mean change
from baseline (95% CI) was −16.2 (−30.2, −2.1) be-
tween the high-dose OFS + P group and control group
and −11.5 (−25.6, 2.7) between the low-dose OFS + P
group and control group. Figure 4 presents the mean
glucose concentration-time profile curves of the three
treatment groups.
The week 3 adjusted geometric mean fasting insulin
value was higher in the control group than both the high
and low-dose OFS + P groups (Table 4). Relative to the
control group, mean fasting insulin was reduced 16% in
the high-dose OFS + P group (ratio: 0.84, 95% CI: 0.70,
1.01) and reduced 12% in the low dose OFS + P group
(ratio: 0.88, 95% CI: 0.73, 1.06). Similarly, the week 3
adjusted geometric mean insulin AUC was higher in
the control group, than in either the high or low dose
OFS + P groups. Relative to the control group, mean
insulin AUC was reduced by 10% in the high-dose
OFS + P group (ratio: 0.90, 95% CI: 0.79, 1.04) and was
reduced by 17% in the low-dose OFS + P group (ratio:
0.83, 95% CI: 0.73, 0.96). Figure 5 presents the mean insu-
lin concentration-time profile curves of the three treat-
ment groups.
Figure 3 Mean (SEM) observed SLIM rating scale–time profile.
Table 3 Subjective ratings of appetite AUC0−4 hours
Parameter High dose OFS + P (N = 30) Low dose OFS + P (N = 29) Control (N = 29)
Baseline SLIM rating: Mean (SD) 188.1 (33.9) 164.9 (53.6) 191.9 (44.0)
SLIM rating at week 3: Mean (SD) 200.4 (39.2) 175.6 (50.1) 185.9 (52.2)
Mean change1 (SD) 12.4 (37.7) 10.8 (33.2) - 6.0 (31.1)
LS Mean change2 13.8 (6.0) 6.9 (6.2) - 3.7 (6.2)
95% CI of LS mean change 1.8, 25.8 - 5.5, 19.4 - 15.9, 8.6
Difference from control3 (SE) 17.5 (8.6) 10.6 (8.9)
95% CI of difference from control 0.5, 34.5 −7.0, 28.3
1Mean Change was calculated as (Week 3 Mean–Baseline Mean).
2LS Mean Change adjusted for baseline Slim Scale AUC0-4hr effect, using analysis of covariance model.
3The difference from control is the difference in the LS Mean Changes of the active treatment minus the control. Overall treatment effect p-value = 0.1279.
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Table 4 Fasting glucose, fasting insulin, HOMA IR and matsuda index
Parameter High dose OFS + P (N = 30) Low dose OFS + P (N = 29) Control (N = 29)
Fasting glucose (mg/dl)
Baseline mean (SD) 93.8 (10.41) 94.2 (8.55) 90.3 (10.00)
Week 3 mean (SD) 90.9 (7.95) 94.0 (7.71) 91.5 (9.58)
Week 3 LS mean change adjusted for baseline −2.34 0.57 −0.06
LS Mean difference from control (95% CI) −2.28 (−6.03, 1.46) 0.63 (−3.15, 4.42)
Fasting insulin (pmol/L)
Baseline geometric mean (SD log-scale) 37.5 (0.59) 40.6 (0.56) 40.4 (0.49)
Week 3 geometric mean (SD log-scale) 34.0 (0.52) 37.8 (0.54) 42.8 (0.61)
Week 3 geometric LS mean adjusted for baseline (SE log-scale) 35.4 (0.07) 37.0 (0.07) 42.0 (0.07)
Geometric LS mean ratio relative to control (95% CI) 0.84 (0.70, 1.01) 0.88 (0.73, 0.1.06)
Matsuda index
Baseline geometric mean (SD log-scale) 11.5 (0.56) 9.9 (0.55) 10.4 (0.52)
Week 3 geometric mean (SD log-scale) 11.7 (0.49) 10.2 (0.53) 8.8 (0.60)
Week 3 geometric LS mean adjusted for baseline (SE log-scale) 10.9 (0.06) 10.8 (0.06) 9.0 (0.06)
Geometric LS mean ratio relative to control (95% CI) 1.22 (1.04, 1.43) 1.21 (1.03, 1.42)
(N = 25) (N = 25) (N = 26)
HOMA-IR
Baseline geometric mean (SD log-scale) 0.79 (0.506) 0.87 (0.422) 0.79 (0.447)
Week 3 geometric mean (SD log-scale) 0.71 (0.404) 0.78 (0.452) 0.91 (0.507)
Week 3 geometric LS mean adjusted for baseline (SE log-scale) 0.75 (0.067) 0.78 (0.067) 0.92 (0.066)
Geometric LS mean ratio relative to control (95% CI) 0.82 (0.68, 0.98) 0.85 (0.70, 1.02)
For fasting insulin, HOMA-IR and Matsuda Index log-transformation was required to improve distributional properties. The dependent variable in the ANCOVA was
the log of the week 3 result. The LS means were adjusted for log of baseline, using an analysis of covariance model.
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insulin resistance and an increase in the Matsuda Index
may imply an increase in insulin sensitivity. Table 4 pre-
sents a summary for these parameters. The week 3 ad-
justed geometric mean HOMA-IR was higher in theFigure 4 Mean glucose concentrations fasting and over 4 h
post-prandial at baseline and after 3 weeks of treatment. Error
bars represent the mean + SEM. OFS, oligofructose; P, apple pectin.control group (0.92), than in either the high dose (0.75)
or low dose (0.78) OFS + P groups. Relative to the con-
trol group, mean HOMA-IR was reduced by 18% in the
high dose OFS + P group (ratio: 0.82, 95% CI: 0.68, 0.98)
and by 15% in the low dose OFS + P group (ratio: 0.85,
95% CI: 0.70, 1.02).Figure 5 Mean insulin concentrations fasting and over 4 h
post-prandial at baseline and after 3 weeks of treatment. Error
bars represent the mean + SEM. OFS, oligofructose; P, apple pectin.
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was lower in the control group (9.0) than in either the
high dose (10.9) or low dose (10.8) OFS + P groups. Rela-
tive to the control group, mean Matsuda Index was
increased by 22% and 21% in the high and low dose
groups, respectively (Table 4).
Body weight
Overall there was no statistically significant difference in
body weight (measured in kg) among the three treatment
groups (p = 0.1047). The difference in the LS mean changes
from baseline (95% CI) was −0.6 (-1.1, −0.04) between the
high-dose OFS + P group and control group and -0.3 (-0.8,
0.3) between the low-dose OFS + P and control group.
Adverse events
At least one AE was reported by 14 (43.8%) high dose
OFS + P subjects, 9 (28.1%) low dose OFS + P subjects,
and 8 (25.0%) control subjects. The most commonly re-
ported AEs were flatulence, constipation, diarrhea, upper
respiratory tract infection, and headache. The AEs were
mild-moderate in intensity; also no serious AEs were re-
ported by the subjects.
Gastrointestinal tolerability
A higher percentage of subjects experienced gas/bloating
during the last 7 days of treatment in the high and low
dose OFS + P groups (63.3% and 69.0%, respectively), as
compared to the control group (34.5%). Similar results
were reported for flatulence in the last 7 days of treat-
ment, with 70% of the high dose subjects, 58.6% of the
low dose subjects, and 44.8% of the control subjects ex-
periencing this event.
A higher percentage of subjects reported diarrhea and
gastrointestinal cramping in the last 7 days of treatment
as occurring “somewhat more” and “much more than
usual” in the high dose group, 33.3% and 26.7%, respect-
ively, as compared to 10.3% and 13.8% of subjects in the
low dose group.
Constipation in the last 7 days of treatment was expe-
rienced by more control subjects, 27.6%, as compared to
23.3% high dose subjects and 17.2% low dose subjects.
Nausea in the last 7 days of treatment was reported by 1
or 2 subjects in each treatment group.
Discussion
Given that obesity and its associated co-morbidities are
at epidemic levels, it is relevant to examine whether
combinations of dietary fiber or fiber supplements are
effective therapies that promote satiety and reduce en-
ergy intake. The scientific literature documents several
favorable effects of dietary fiber on calorie intake and
glucose homeostasis. Previous clinical research suggests
that OFS and pectin each produce effects on satiety,glycemic parameters, and weight loss in humans [8-19].
To our knowledge, this exploratory study is the first to
examine whether dietary supplementation with a com-
bination of OFS and pectin produces greater changes in
satiety, glycemic parameters, and body weight compared
to control. In general, there were no robust effects of the
combination of OFS and pectin on energy intake of an
ad libitum test meal, body weight, or subjective appetite
ratings or glycemic parameters following a mixed meal
challenge.
The baseline energy intakes differed among the three
groups. The energy intake in the low dose OFS + P
group was about 200 kcal higher as compared with the
high dose group and about 160 kcal higher as compared
with control. The change from baseline in energy intake
showed a reduction over the three week period of 6.6%
and 10.4% in the high and low dose OFS + P groups, as
compared to 0.4% in the control group. Consequently,
when adjusted for effects of baseline intake, both the
high and low dose OFS + P groups demonstrated poten-
tially meaningful reductions in energy intake, but the re-
sults were not statistically significant. Likewise, both the
high and low dose OFS + P groups demonstrated increased
overall ratings of fullness when adjusted for baseline ef-
fects, but the differences among the treatment groups
were not significant. Additionally, there was large variabil-
ity in energy intake and appetite ratings.
There were no meaningful differences in changes from
baseline in fasting glucose or insulin levels observed in
any of the treatments. There were small placebo-corrected
reductions in glucose AUC across breakfast for low and
high dose OFS + P. However, as shown in Figures 4 and 5,
the 5 g maltodextrin may have augmented the glucose and
insulin excursions in the control group following the
breakfast meal, in which 40 g of carbohydrate was con-
sumed. There was little change in glucose and insulin
AUC (0-4 h) with low dose OFS + P following the break-
fast meal challenge, whereas there was a suggestion of a
reduction of glucose AUC (0-4 h) with high dose OFS + P
across the breakfast meal when compared to the low dose
group. It is interesting to note that in the subset of sub-
jects in the high dose group who actually had glucose
reductions, insulin was also reduced in the majority of
cases, suggesting improved glucose disposal with lower in-
sulin levels (data not shown). This is consistent with
the changes in HOMA-IR and Matsuda Index in the
two OFS + P treated groups that indicate an improvement
in insulin sensitivity relative to control. However, much of
the difference is due to alteration of the glucose/insulin
dynamics in the maltodextrin control group.
A small difference in the change from baseline body
weight was observed between the high dose OFS + P and
control groups at week 3. However this was primarily
due to weight gain in the control group. The change
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three week period of 0.1% and 0.5% in the high and low
dose OFS + P groups, as compared to 0.7% in the control
group. Given that the high dose OFS + P and control
treatments were matched for (estimated) metabolizable
energy, this observation suggests that high dose OFS + P
subjects may have compensated for the additional en-
ergy intake in the study treatment by eating less across
the study period, whereas control subjects did not. Fur-
ther study would be necessary to determine whether
regular consumption of OFS + P supports body weight
maintenance, or promotes weight loss when combined
with a hypocaloric diet.
Overall, the results of this study do not provide strong
support for the regular consumption of OFS + P for the
short-term management of satiety. One possible explan-
ation may be that the doses selected for either OFS or
pectin were not optimal. For example, the doses selected
in our study may not have been high enough since both
16 g of OFS [10] as well as 15 g of pectin [16] have each
been shown to effectively increase the acute sensation of
satiety in adult obese patients. Conversely, 5 g of pectin,
as was used in our high-dose OFS + P group, produced
satiety in healthy-weight men and women when assessed
acutely [15].
The safety and tolerability results in the present study
were consistent with what is expected from consumption
of dietary fibers. The most commonly observed AEs were
gastrointestinal in nature, none of which were serious.
Conclusion
In conclusion, dietary supplementation of OFS + P tested
at two doses did not produce statistically significantly
greater reductions from baseline in energy intake of a
test meal compared to the control. Although this pilot
study did not demonstrate significant changes, we ob-
served a directional benefit in ad libitum energy intake
for high dose OFS + P and low dose OFS + P compared
to control, with a greater reduction in kilocalories in the
low dose comparison. Similarly, there may be improve-
ment in insulin sensitivity. Further research on combina-
tions of dietary fiber and other potential dietary therapies
is warranted.
Abbreviations
AE: Adverse Events; ANCOVA: Analysis of covariance; cGMP: Current good
manufacturing practices; CON: Maltodextrin control; HOMA-IR: Homeostasis
Model Assessment Insulin Resistance; ITT: Intent-to-Treat; LS: Least-Squares;
OFS: Oligofructose; P: Apple pectin; PP: Per-protocol; SCFA: Short-chain fatty
acids; SLIM Scale: Satiety Labeled Intensity Magnitude.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed to conception and design of the study; A.W and R.K.
analyzed the data; all authors contributed to the interpretation of the data,drafting of the article, provided critical revision of the article for intellectual
content, and approved final content.
Acknowledgements
We thank Shalini Dwivedi, Inventiv Health Clinical, for helping with
preparation of the manuscript.
Funding
This study was funded by GlaxoSmithKline Consumer Healthcare. All authors
were employees of GlaxoSmithKline at the time this study was conducted.
D.S.’s current affiliation is Pfizer Consumer Healthcare, Madison, NJ, USA.
Author details
1Medical Affairs, Consumer Healthcare, GlaxoSmithKline, Parsippany, NJ, USA.
2Discovery Medicine, GlaxoSmithKline, Five Moore Drive, MS N2-3208,
Research Triangle Park, NC 27709, USA. 3Statistics and Programming,
GlaxoSmithKline, Research Triangle Park, NC, USA. 4Biostatistics, Consumer
Healthcare, GlaxoSmithKline, Parsippany, NJ, USA.
Received: 21 January 2014 Accepted: 12 May 2014
Published: 17 May 2014
References
1. Kristensen M, Jensen MG: Dietary fibres in the regulation of appetite and
food intake. Importance of viscosity. Appetite 2011, 56(1):65–70.
2. Bouhnik Y, Raskine L, Simoneau G, Vicaut E, Neut C, Flourie B, Brouns F,
Bornet FR: The capacity of nondigestible carbohydrates to stimulate fecal
bifidobacteria in healthy humans: a double-blind, randomized, placebo-
controlled, parallel-group, dose–response relation study. Am J Clin Nutr
2004, 80:1658–1664.
3. Oh D, Lagakos W: The role of G-protein-coupled receptors in mediating
the effect of fatty acids on inflammation and insulin sensitivity. Curr Opin
Clin Nutr Metab Care 2011, 14(4):322–327.
4. Pereira MA, Ludwig DS: Dietary fiber and body-weight regulation: Observations
and mechanisms. Pediatr Clin North Am 2001, 48(4):969–980.
5. Delzenne NM, Neyrinck AM, Cani PD: Gut microbiota and metabolic
disorders: how prebiotic can work? Br J Nutr 2013, 109:S81–S85.
6. Delzenne NM, Cani PD, Daubioul C, Neyrinck AM: Modulation of glucagon-
like peptide 1 and energy metabolism by inulin and oligofructose:
experimental data. J Nutr 2007, 137(11 Suppl):2547S–2551S.
7. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I,
Wolvers D, Watzi B, Szajewska H, Stahl B, Guarner F, Repondek F, Whelan K,
Coxam V, Davicco MJ, Leotoing L, Wittrant Y, Delzenne NM, Cani PD,
Neyrinck AM, Meheust A: Prebiotic effects: Metabolic and health benefits.
Br J Nutr 2010, 104(SUPPL.2):S1–S63.
8. Parnell JA, Reimer RA: Weight loss during oligofructose supplementation
is associated with decreased ghrelin and increased peptide YY in
overweight and obese adults. Am J Clin Nutr 2009, 89(6):1751–1759.
9. Antal M, Regöly-Mérei A, Biró L, Arató G, Schmidt J, Nagy K, Greiner E,
Lasztity N, Szabo C, Péter S, Martos E: Effects of oligofructose containing
diet in obese persons. Orv Hetil 2008, 149(42):1989–1995.
10. Cani PD, Joly E, Horsmans Y, Delzenne NM: Oligofructose promotes satiety
in healthy human: a pilot study. Eur J Clin Nutr 2006, 60(5):567–572.
11. Verhoef SPM, Meyer D, Westerterp KR: Effects of oligofructose on appetitie
profile, glucagon-like peptide 1 and peptide YY3-36 concentrations and
energy intake. Brit J Nutr 2011, 106:1757–1762.
12. Luo J, Rizkalla SW, Alamowitch C, Boussairi A, Blayo A, Barry JL, Laffitte A,
Guyon F, Bornet RJ, Slama G: Chronic consumption of short-chain
fructooligosaccharides by healthy subjects decreased basal hepatic
glucose production but had no effect on insulin-stimulated glucose
metabolism. Am J Clin Nutr 1996, 63:939–945.
13. Luo J, Yperselle MV, Rizkalla SW, Rossi F, Bornet FRJ, Slama G: Chronic
consumption of short-chain fructooligosaccharides does not affect basal
hepatic glucose production or insulin resistance in type 2 diabetics.
J Nutr 2000, 130:1572–1577.
14. Perrigue M, Carter B, Roberts SA, Drewnowski A: A low-calorie beverage
supplemented with low-viscosity pectin reduces energy intake at a
subsequent meal. J Food Sci 2010, 75(9):H300–H305.
15. Tiwary CM, Ward JA, Jackson BA: Effect of pectin on satiety in healthy US
army adults. J Am Coll Nutr 1997, 16(5):423–428.
Savastano et al. Nutrition Journal 2014, 13:45 Page 11 of 11
http://www.nutritionj.com/content/13/1/4516. Di Lorenzo C, Williams CM, Hajnal F, Valenzuela JE: Pectin delays gastric
emptying and increases satiety in obese subjects. Gastroenterology 1988,
95(5):1211–1215.
17. Holt S, Heading RC, Carter DC, Prescott LF, Tothill P: Effect of gel fibre on
gastric emptying and absorption of glucose and paracetamol.
Lancet 1979, 313(8117):636–639.
18. Sanaka M, Yamamoto T, Anjiki H, Nagasawa K, Kuyama Y: Effects of agar
and pectin on gastric emptying and post-prandial glycaemic profiles in
healthy human volunteers. Clin Exp Pharm Phys 2007, 34:1151–1155.
19. Schwartz SE, Levine RA, Weinstock RS, Petokas S, Mills CA, Thomas FD:
Sustained pectin ingestion: effect on gastric emptying and glucose
tolerance in non-insulin-dependent diabetic patients. Am J Clin Nutr 1988,
48:1413–1417.
20. Stunkard AJ, Messick S: The three factor eating inventory to measure
dietary restraint, disinhibition and hunger. J Psychosom Res 1985,
29(1):71–83.
21. Cardello AV, Schutz HG, Lesher LL, Merrill E: Development and testing of a
labeled magnitude scale of perceived satiety. Appetite 2005, 44(1):1–13.
22. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling.
Diabetes Care 2004, 27(6):1487–1495.
23. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin
clamp. Diabetes Care 1999, 22(9):1462–1470.
doi:10.1186/1475-2891-13-45
Cite this article as: Savastano et al.: Effect of two dietary fibers on satiety
and glycemic parameters: a randomized, double-blind, placebo-controlled,
exploratory study. Nutrition Journal 2014 13:45.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
